🔍

KOPRAN - Kopran

📊 NSE: KOPRAN 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 9:00

📢 Recent Corporate Announcements

Kopran Promoters Declare No New Share Encumbrances for FY 2024-25; Holding at 44.46%

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 10 Apr 2026, 05:24 PM

Kopran Limited's promoter group has filed a formal declaration under SEBI (SAST) Regulation 31(4) for the financial year ending March 31, 2025. The promoters confirmed that no additional encumbrances or pledges were placed on their shareholding during the year, beyond what was already disclosed to the exchanges. As of March 31, 2025, the promoter and promoter group collectively hold 2,14,49,203 shares. This stake represents 44.46% of the company's total voting capital, providing transparency regarding the stability of promoter holdings.

Promoter and Promoter Group hold 2,14,49,203 equity shares as of March 31, 2025
Total promoter stake stands at 44.46% of the company's diluted share capital
Official declaration confirms no new direct or indirect encumbrances were made during FY 2024-25
The filing includes 20 promoter entities and individuals, including Oricon Enterprises Ltd and Parijat Enterprises

💡 This is a routine regulatory disclosure that confirms no hidden pledges were created by the promoters. Investors should view this as a standard transparency measure and continue to monitor the company's operational performance.

Kopran Promoters Confirm No New Encumbrances; Total Holding at 44.46% for FY25

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 10 Apr 2026, 05:24 PM

Kopran Limited's promoters have filed their annual declaration under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations for the financial year ending March 31, 2025. The filing confirms that no new encumbrances or pledges were created on promoter shares during the year, beyond what was already disclosed to the exchanges. The total promoter group holding is reported at 2,14,49,203 shares, representing 44.46% of the company's equity. This disclosure is a standard annual transparency measure required by Indian market regulators to monitor promoter share activity.

Promoter group holds 2,14,49,203 equity shares as of March 31, 2025.
Total promoter stake stands at 44.46% of the company's voting capital.
Declaration confirms no undisclosed encumbrances were made during the 2024-25 fiscal year.
Submission made in compliance with Regulation 31(4) of SEBI (SAST) Regulations, 2011.

💡 No immediate action is required as this is a standard annual compliance disclosure. Investors should note the stable promoter holding and the absence of new share pledges as a sign of transparency.

Kopran Receives NCLT Order to Convene Meetings for Merger with Kopran Laboratories

🟢 POSITIVE ⭐ 8/10

M&A 📅 10 Apr 2026, 04:30 PM

Kopran Limited has received a significant regulatory update regarding its proposed merger with Kopran Laboratories Limited. The National Company Law Tribunal (NCLT), Mumbai Bench, issued an order on April 09, 2026, directing the company to hold meetings for its equity shareholders and creditors. This merger, first announced in March 2025, aims to consolidate the transferor company into the listed entity. This procedural step is a critical milestone toward obtaining final legal approval for the amalgamation.

NCLT Mumbai Bench issued a direction order on April 09, 2026, for the merger process.
The scheme involves the merger by absorption of Kopran Laboratories Limited into Kopran Limited.
Mandatory meetings must be convened for Equity Shareholders, Secured Creditors, and Unsecured Creditors.
The merger process was originally initiated and informed to exchanges on March 20, 2025.
The consolidation is being executed under Sections 230 to 232 of the Companies Act, 2013.

💡 Investors should monitor the outcome of the upcoming shareholder and creditor meetings as a 'Yes' vote is required to proceed. The merger is likely to simplify the corporate structure and potentially improve operational synergies.

Kopran Clarifies Significant Price Movement; No Undisclosed Material Information

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 10 Apr 2026, 12:24 PM

Kopran Limited has responded to a surveillance query from the National Stock Exchange regarding significant movement in its share price. The company officially stated on April 10, 2026, that it has disclosed all material information and events as per SEBI regulations. Management clarified that there is no withheld information that could impact the stock price. Consequently, the company attributes the recent price volatility purely to market-driven factors.

NSE issued a surveillance query (Ref. No.: NSE/CM/Surveillance/16744) dated April 09, 2026.
Company confirmed compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.
Management explicitly stated that the increase in share price is purely market driven.
No material events or information with a bearing on price remain undisclosed to the exchanges.

💡 Investors should remain cautious as the company has confirmed no new fundamental developments to justify the recent price movement. Focus on upcoming quarterly results and industry trends rather than speculative price volatility.

Kopran Limited Submits SEBI Regulation 74(5) Compliance Certificate for Q4 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 09 Apr 2026, 02:58 PM

Kopran Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the period ended March 31, 2026. The filing confirms that the company and its Registrar, Bigshare Services Pvt. Ltd., have processed all dematerialization requests within the stipulated timelines. This includes the mutilation and cancellation of physical certificates and the updating of the register of members. Such filings are standard administrative procedures to ensure the integrity of electronic shareholding records.

Compliance certificate issued for the quarter ended March 31, 2026.
Confirmation that dematerialization requests were processed and securities listed on exchanges.
Physical certificates were mutilated and cancelled within the mandated 15-day window.
Verification provided by Registrar and Share Transfer Agent, Bigshare Services Pvt. Ltd.

💡 No action is required from investors as this is a routine regulatory filing confirming standard administrative compliance.

Kopran Limited Clarifies Significant Increase in Trading Volume

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 08 Apr 2026, 08:36 AM

Kopran Limited has responded to a surveillance query from the National Stock Exchange (NSE) regarding a significant spurt in trading volume. In its official response dated April 08, 2026, the company stated that it has disclosed all material information required under Regulation 30 of SEBI LODR. The management clarified that there is no undisclosed event or information that would impact the scrip's volume. Consequently, the company has attributed the recent increase in trading activity to being purely market-driven.

NSE issued a surveillance query (Ref. No. NSE/CM/Surveillance/16667) on April 07, 2026.
Company responded on April 08, 2026, confirming no material information is withheld.
Management explicitly stated that the volume increase is purely market-driven.
The company remains in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

💡 As the company has clarified there is no new material development, investors should avoid speculative trading based solely on volume spurts. Continue to monitor the stock for fundamental performance or actual corporate announcements.

Kopran Limited to Close Trading Window from April 1, 2026 for Q4 and FY26 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 24 Mar 2026, 08:39 AM

Kopran Limited has announced the closure of its trading window effective April 1, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations. This closure is ahead of the declaration of the audited financial results for the fourth quarter and the full financial year ending March 31, 2026. The window will remain closed for directors, designated persons, and their immediate relatives until 48 hours after the results are officially announced. The specific date for the board meeting to approve these results will be communicated in a separate future filing.

Trading window closure begins on April 1, 2026.
Closure pertains to the audited financial results for Q4 and FY ending March 31, 2026.
The window will reopen 48 hours after the financial results are declared to the exchanges.
Restriction applies to all Directors, Designated Persons, and their immediate relatives.

💡 This is a routine regulatory filing with no direct impact on stock fundamentals. Investors should monitor for the future announcement of the board meeting date to evaluate the company's year-end financial performance.

Adarsh Somani Resigns as Non-Executive Director of Kopran Limited Effective March 2026

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 17 Mar 2026, 03:51 PM

Mr. Adarsh Somani has resigned as a Non-Executive Non-Independent Director of Kopran Limited, effective March 17, 2026. The resignation is a result of a Memorandum of Family Settlement dated September 01, 2025, executed among the company's promoters regarding shareholding and directorships. Mr. Somani will also step down from his roles in the Stakeholder Relationship, Risk Management, and Corporate Affairs Committees. The company disclosed that the outgoing director holds zero shares in the entity.

Resignation of Mr. Adarsh Somani (DIN: 00192609) effective from March 17, 2026
Departure is in accordance with a Memorandum of Family Settlement dated September 01, 2025
Outgoing director steps down from three key board committees including Risk Management
Mr. Adarsh Somani holds nil (0) shares in the company as of the resignation date

💡 This is a planned administrative change linked to a promoter-level family settlement and is unlikely to impact daily operations. Investors should monitor for any subsequent changes in promoter shareholding patterns as per the 2025 settlement.

Kopran Receives NSE 'No Objection' for Merger with Kopran Laboratories

🟢 POSITIVE ⭐ 8/10

M&A 📅 28 Feb 2026, 12:29 PM

Kopran Limited has received a 'No Objection' observation letter from the National Stock Exchange (NSE) on February 27, 2026, regarding its proposed merger with Kopran Laboratories Limited. This follows the initial board approval from March 20, 2025, and allows the company to proceed with filing the scheme before the NCLT. The company is now required to provide detailed disclosures to shareholders, including a 3-year financial track record (Revenue, PAT, EBITDA) and the impact on promoter shareholding. The merger aims to consolidate operations, though the final scheme remains subject to NCLT and other regulatory approvals.

Received NSE 'No Objection' on February 27, 2026, for the merger of Kopran Laboratories into Kopran Limited.
The observation letter is valid for 6 months, requiring the scheme to be submitted to the NCLT by late August 2026.
Mandatory disclosure of 3-year audited financials (Revenue, PAT, EBITDA) for both entities is required for shareholder approval.
Company must prominently disclose any increase in promoter shareholding and the specific rationale for the swap ratio.
The scheme involves the transfer of all liabilities from the unlisted Transferor Company to the listed Transferee Company.

💡 Investors should review the upcoming shareholder notice for the specific swap ratio and the impact on promoter equity dilution. Monitor the NCLT approval process as the next major milestone for the consolidation.

Kopran Receives BSE 'No Adverse Observation' for Merger with Kopran Laboratories

🟢 POSITIVE ⭐ 8/10

M&A 📅 27 Feb 2026, 04:29 PM

Kopran Limited has received a 'no adverse observation' letter from BSE Limited regarding its proposed merger with Kopran Laboratories Limited. This regulatory milestone follows the initial board approval granted on March 20, 2025. The company is now authorized to proceed with filing the scheme before the National Company Law Tribunal (NCLT) within the next six months. The merger remains subject to further approvals from the NCLT, shareholders, and other regulatory bodies.

BSE issued the 'no adverse observation' letter on February 26, 2026, for the Scheme of Amalgamation.
The merger involves the absorption of Kopran Laboratories Limited (Transferor) into Kopran Limited (Transferee).
The observation letter is valid for six months, during which the company must submit the scheme to the NCLT.
SEBI has mandated detailed disclosures in the shareholder notice, including a cost-benefit analysis and changes in promoter shareholding.
The company must ensure that financial data used for the valuation report is not more than six months old at the time of filing.

💡 Investors should monitor the upcoming NCLT filing and review the detailed explanatory statement for the swap ratio and potential synergy benefits. The stock may see positive sentiment as the consolidation process moves toward the final legal stages.

Kopran Limited Reports Cyber-attack on Server Data at Khopoli Factory

🔵 WATCH ⭐ 6/10

OTHER 📅 20 Feb 2026, 04:42 PM

Kopran Limited has disclosed a cybersecurity incident involving unauthorized access to its computer server data at the Khopoli factory. The breach was identified on February 20, 2026, at approximately 3:50 p.m., prompting immediate restrictive actions by the company. Currently, Kopran is working with external cybersecurity experts to conduct a root cause analysis and assess any potential data or operational impact. While the company has taken steps to secure its systems, the full extent of the breach and its financial implications remain under investigation.

Unauthorized access to computer server data detected at the Khopoli factory on February 20, 2026
Incident officially reported to the Compliance Officer at 3:50 p.m. on the same day
Immediate measures implemented to restrict further unauthorized access to the company's servers
Cybersecurity experts engaged for a thorough impact assessment and root cause analysis

💡 Investors should monitor subsequent filings for updates on data recovery and potential operational disruptions. Maintain a cautious stance until the company confirms no sensitive intellectual property or financial data was compromised.

Kopran Q3 Revenue Rises 17% YoY to ₹194 Cr; PAT Dips 10% to ₹9.34 Cr

🔵 WATCH ⭐ 7/10

EARNINGS 📅 22 Jan 2026, 04:47 PM

Kopran Limited reported a 16.8% YoY increase in consolidated revenue from operations to ₹194.28 crore for the quarter ended December 31, 2025. Despite the revenue growth, consolidated net profit declined by 10.1% YoY to ₹9.34 crore, down from ₹10.40 crore in the same quarter last year. On a sequential basis, the company returned to profitability after reporting a net loss of ₹9.92 crore in the previous quarter (Q2 FY26). For the nine-month period, net profit remains significantly lower at ₹6.87 crore compared to ₹28.87 crore in the previous year.

Consolidated Revenue from Operations grew 16.8% YoY to ₹194.28 crore in Q3 FY26.
Consolidated Net Profit for the quarter stood at ₹9.34 crore, a 10.1% decline from ₹10.40 crore in Q3 FY25.
The company achieved a significant sequential turnaround from a net loss of ₹9.92 crore in Q2 FY26.
Nine-month (9M FY26) consolidated PAT dropped sharply to ₹6.87 crore from ₹28.87 crore in 9M FY25.
Basic EPS for the quarter was ₹1.93, compared to ₹2.16 in the corresponding quarter of the previous year.

💡 Investors should note the sequential turnaround from a loss in Q2, but remain cautious due to the significant year-on-year decline in nine-month cumulative profitability. Monitor the company's ability to sustain this recovery and manage operating costs in the upcoming quarters.

Kopran Q3 FY26 Net Profit Recovers to ₹9.34 Cr; Revenue Up 17% YoY to ₹194.28 Cr

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 22 Jan 2026, 04:20 PM

Kopran Limited reported a strong sequential recovery in Q3 FY26, with revenue reaching ₹194.28 crore, a 64.7% increase over Q2 FY26. Net profit returned to the black at ₹9.34 crore after a loss of ₹9.92 crore in the previous quarter, though it remains slightly lower than the ₹10.40 crore earned in Q3 FY25. EBITDA margins saw a significant rebound to 10.42% from a low of 2.51% in Q2. The company's revenue was well-balanced between its API (₹100.05 crore) and Formulations (₹92.31 crore) segments, with a heavy focus on exports.

Revenue from operations grew 16.8% YoY to ₹194.28 crore and 64.7% QoQ.
Net Profit stood at ₹9.34 crore, recovering from a net loss of ₹9.92 crore in Q2 FY26.
EBITDA margin improved significantly to 10.42% compared to 2.51% in the preceding quarter.
API segment revenue reached ₹100.05 crore, with exports contributing 67% of the total API sales.
Formulations segment contributed ₹92.31 crore, with Penicillin-based products accounting for 59% of the mix.

💡 Investors should monitor the sustainability of the margin recovery and the progress of the new API facility at Panoli, Gujarat. The sharp sequential turnaround suggests operational issues from the previous quarter have been addressed.

Kopran Q3 Results: Revenue Grows 17% YoY to ₹194 Cr, PAT at ₹9.3 Cr with Strong QoQ Turnaround

🔵 WATCH ⭐ 7/10

EARNINGS 📅 22 Jan 2026, 03:00 PM

Kopran Limited reported a consolidated revenue of ₹194.28 crore for Q3 FY26, a 16.8% increase compared to ₹166.24 crore in the same quarter last year. The company achieved a significant sequential turnaround, posting a PAT of ₹9.34 crore compared to a loss of ₹9.92 crore in Q2 FY26. However, on a year-on-year basis, PAT declined by approximately 10% from ₹10.40 crore. The nine-month performance remains weak, with cumulative PAT falling to ₹6.87 crore from ₹28.87 crore in the previous year, primarily due to higher expenses and forex losses earlier in the fiscal year.

Consolidated Revenue from Operations rose 16.8% YoY to ₹19,427.98 Lakhs.
Achieved a sharp QoQ turnaround with a PAT of ₹933.96 Lakhs versus a loss of ₹992.32 Lakhs in the previous quarter.
9M FY26 PAT stands at ₹686.57 Lakhs, a significant drop from ₹2,887.46 Lakhs in 9M FY25.
Foreign Exchange Loss of ₹247.22 Lakhs was recorded in the consolidated results for the quarter.
Consolidated Basic EPS for the quarter stood at ₹1.93 compared to ₹2.16 in the year-ago period.

💡 Investors should focus on the company's ability to maintain this sequential recovery in margins and revenue. While the QoQ turnaround is positive, the sharp decline in nine-month cumulative profits suggests long-term cost pressures that warrant a cautious approach.

GST Authorities Conduct Search at Kopran's Mumbai and Raigad Facilities

🔵 WATCH ⭐ 6/10

REGULATORY 📅 21 Jan 2026, 04:57 PM

Maharashtra State GST authorities initiated a search at Kopran Limited's registered office in Mumbai and its manufacturing facilities in Khopoli, Raigad on January 21, 2026. The search was conducted under Section 67 of the Maharashtra Goods and Services Tax Act, 2017. While the search is ongoing, the company has stated that normal operations remain unaffected and no specific allegations of violations have been shared by the officials yet. There is currently no quantifiable financial impact reported, but the situation warrants monitoring for potential tax liabilities or penalties.

Search initiated by Deputy Commissioner of State Tax, SGST (Maharashtra) on January 21, 2026.
Action taken under Section 67 of the Maharashtra Goods and Services Tax Act, 2017.
Locations involved include the Mumbai registered office and Khopoli (Raigad) manufacturing works.
Company reports no impact on normal operations of factories or offices during the search process.
No specific violation details or financial implications have been communicated by authorities as of the announcement.

💡 Investors should monitor further disclosures regarding the outcome of the GST search to assess any potential tax demands or penalties. Maintain a cautious stance until the company clarifies the nature of the alleged contraventions.

View All KOPRAN Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Revenue for HY FY26 was INR 253.13 Cr. The API segment contributes approximately 50-55% of total revenue, while the Formulations segment accounts for the remaining 45-50%. FY25 total operating income was INR 629.60 Cr, representing a marginal growth of 2.39% compared to INR 614.9 Cr in FY24.

Geographic Revenue Split

The company has a significant export presence, catering to regions including Africa, Canada, the Middle East, the United Kingdom, and Southeast Asia. Specific percentage splits per region are not disclosed, but export operations are a primary driver of revenue and forex risk.

Profitability Margins

Operating profitability has been volatile, ranging between 9.57% and 13.31% over the three fiscal years ending FY25. FY25 PAT margin was 6.12% (INR 38.55 Cr), down from 8.29% (INR 50.9 Cr) in FY24, a decline of 24.3% YoY due to raw material price volatility.

EBITDA Margin

EBITDA margin for HY FY26 stood at 6.75% (INR 17.09 Cr). Quarterly performance showed extreme volatility, with Q2 FY26 margin at 2.51% compared to 10.45% in Q1 FY26 and 9.72% in Q2 FY25, primarily impacted by a forex loss of INR 8.24 Cr in Q2 FY26.

Capital Expenditure

The company maintains a comfortable financial risk profile in the absence of any major debt-funded capex plans over the medium term. Specific historical capex figures in INR Cr are not disclosed in the provided documents.

Credit Rating & Borrowing

CRISIL has placed the company's ratings on 'Rating Watch with Developing Implications' following the proposed amalgamation of Kopran Laboratories Limited. Interest coverage was healthy at 8.09 times for FY25, with gearing remaining below 0.30 times for the past five fiscal years.

⚙️ Operational Drivers

Raw Materials

Key Starting Materials (KSMs) are the primary raw materials. The API segment (50-55% of revenue) is highly susceptible to price volatility in these materials, which directly impacts the group's operating margins.

Import Sources

Not specifically disclosed, though the company mentions aligning with global standards and monitoring international economic conditions for procurement.

Key Suppliers

Not specifically named; however, the company's strategy involves securing two to four suppliers for each Key Starting Material (KSM) to mitigate procurement risks.

Capacity Expansion

Manufacturing facilities are located in Mahad and Khopoli, Maharashtra. Current installed capacity in MT or units and specific expansion timelines are not disclosed in the available documents.

Raw Material Costs

Raw material price volatility led to a moderation in operating profitability to 11.94% in FY25. The company is enhancing its sourcing strategy by developing its own KSMs to reduce cost sensitivity.

Manufacturing Efficiency

Not specifically disclosed, though the company emphasizes investing in advanced technologies and R&D to maintain competitiveness.

Logistics & Distribution

The company employs a dedicated logistics team to proactively manage the supply chain and ensure timely actions to avoid disruptions in global distribution.

📈 Strategic Growth

Growth Strategy

Growth is targeted through the proposed amalgamation of Kopran Laboratories Limited (KLL) into Kopran Limited to consolidate operations. Other strategies include R&D investment in advanced technologies, expansion in therapeutic segments like anti-diabetic and anti-hypertensive, and strengthening global market presence.

Products & Services

The company manufactures and supplies international quality formulations and APIs, including antibiotics, anti-malarials, analgesics, anti-diabetics, anti-infectives, and anti-hypertensives.

Brand Portfolio

Kopran is the primary corporate brand; specific consumer brand names for individual medicines are not listed in the documents.

New Products/Services

The company focuses on diverse therapeutic segments including anti-diabetic, anti-infective, and anti-hypertensive drugs. Specific revenue contribution percentages for new launches are not disclosed.

Market Expansion

Target regions for expansion include Africa, Canada, the Middle East, the United Kingdom, and Southeast Asia, leveraging the promoter's 40+ years of experience.

Strategic Alliances

The company collaborates with global partners to stay updated on technological advancements and innovation in the pharmaceutical sector.

🌍 External Factors

Industry Trends

The industry is characterized by a need for continual innovation and adherence to evolving global regulatory standards. Kopran is positioning itself by diversifying its therapeutic offerings and strengthening its API sourcing.

Competitive Landscape

The company operates in a highly competitive landscape which impacts pricing strategies and overall profitability, especially in the API segment.

Competitive Moat

The company's moat is built on the promoter's 40-year experience, established relationships with stakeholders, and an integrated business model (API + Formulations). Sustainability depends on successful R&D and regulatory compliance.

Macro Economic Sensitivity

The company is sensitive to global economic conditions, inflation, and exchange rate fluctuations, particularly given its heavy reliance on exports.

Geopolitical Risks

Export operations to diverse geographies like the Middle East and Africa expose the company to regional geopolitical shifts and trade policy changes.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to stringent government policies and regulatory frameworks. Non-compliance poses a significant reputational and operational risk.

Environmental Compliance

The company strictly adheres to environmental regulations and regularly files Compliance Reports to safeguard its reputation and maintain profitability.

Taxation Policy Impact

Tax expenses for HY FY26 were INR 0.74 Cr. The company adheres to Indian Accounting Standards (Ind AS) and relevant tax laws.

Legal Contingencies

The proposed amalgamation of Kopran Laboratories Limited is pending approvals from the BSE, NSE, and the National Company Law Tribunal (NCLT). No other specific pending court case values were disclosed.

⚠️ Risk Analysis

Key Uncertainties

Key risks include forex volatility (impacted Q2 FY26 by INR 8.24 Cr), volatile raw material prices for APIs, and the successful completion of the KLL amalgamation.

Geographic Concentration Risk

While specific percentages are missing, the company has high geographic diversification across Africa, Canada, UK, and SE Asia, reducing dependency on any single domestic market.